Mabs directed against the cell surface antigens, CD19 and CD22 conjugated to deglycosylated ricin A chain (dgRTA) have been tested in patients with non-Hodgkin's lymphoma (NHL), but not in ...

In 2017, the agency cleared the CD22-targeting ADC for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), the most common type of ALL. The latest decision ...